

ROMA HEMATOLOGY CONFERENCE THE LYMPHOMAS

Rome, now Roma, October 15-16, 2026

October 15, 2026

13.30 **Introduction**

S. Hohaus (Roma), M. Martelli (Roma), L. Rigacci (Roma)

13.45 **40 years of hematology in 'Via Benevento'**

M. Martelli (Roma)

SESSION I - BASIC/TRANSLATIONAL SCIENCE SHAPING THE FUTURE OF TARGETED THERAPIES IN LYMPHOMA

Chairmen: R. Foà (Roma), G. Gaidano (Novara)

14.15 Introductory key lecture: the Biology of B-cell lymphomas

R. Dalla Favera (New York, USA)

14.35 Genomic/molecular profiling of non-Hodgkin lymphomas (NGS, ctDNA)

D. Rossi (Bellinzona, CH)

14.55 Genomic/molecular profiling of Hodgkin lymphomas (NGS, ctDNA)

E. Tiacci (Perugia)

15.15 Microenvironment, immunological niches and synapses, germinal center TBD

15.35 Signaling pathways and microenvironment crosstalk in lymphomas

S. Casola (Milano)

15.55 Biologic insights into MCL from the MCL0208 study

S. Ferrero (Torino)

16.15 Round Table - Which are emerging targets in lymphomas?

Chairmen: A. Di Napoli (Roma), D. Remotti (Viterbo)

Discussants: S. Casola (Milano), R. Dalla Favera (New York, USA), S. Ferrero (Torino), D. Rossi (Bellinzona, CH), E. Tiacci (Perugia), TBD

16.45 Coffee Break

SESSION II - ACADEMIC RESEARCH LEADING TO CHANGE IN CLINICAL PRACTICE: THREE MILESTONES

Chairmen: M. Ladetto (Alessandria), A. Santoro (Rozzano-MI)

17.00 Interim FDG-PET in advanced classical Hodgkin lymphoma: will the story continue?

M. Hutchings (Copenhagen, DK)

17.20 Primary central nervous system lymphoma from radiotherapy to chemotherapy ... to targeted therapy?

A.J.M. Ferreri (Milano)

17.40 Primary mediastinal B-cell lymphoma

M. Martelli (Roma)

18.00 Round Table - How can academic research contribute to the progress in lymphoma treatment in the future?

Chairmen: R. Foà (Roma), M.C. Cox (Roma)

Discussants: A.J.M. Ferreri (Milano), M. Hutchings (Copenhagen, DK), M. Martelli (Roma)

October 16, 2026

SESSION III - CHANGING TREATMENT ALGORITHMS IN TREATMENT OF AGGRESSIVE LYMPHOMAS

Chairmen: P. Corradini (Milano), M. Martino (Reggio Calabria)

- 8.30 Introductory key lecture: rethinking treatment algorithms in aggressive B-cell lymphomas
G. Salles (New York, USA)
- 8.50 Novel pharmacological paradigms in aggressive B-cell lymphomas
G. Minotti (Roma)
- 9.10 Antibody-drug conjugates
C. Carlo-Stella (Rozzano-MI)
- 9.30 CAR-T in follicular and DLBC lymphoma
A. Di Rocco (Roma)
- 9.50 CAR-T in difficult-to-target lymphomas: T-cell lymphoma and Hodgkin's lymphoma
F. Locatelli (Roma)
- 10.10 Bispecific antibodies in aggressive lymphomas
R. Di Blasi (Paris, FR)
- 10.30 Round table - Sequencing of targeted therapies: What comes first?
Chairmen: S. Hohaus (Roma), U. Vitolo (Candiolo-TO)
Discussants: C. Carlo-Stella (Rozzano-MI), R. Di Blasi (Paris, FR), A. Di Rocco (Roma),
F. Locatelli (Roma), G. Minotti (Roma), G. Salles (New York, USA)
- 11.00 Coffee Break

SESSION IV - LYMPHOMAS WITH GOOD PROGNOSIS: DO NOT HARM

Chairmen: L. Arcaini (Pavia), G. Gini (Ancona)

- 11.15 Introductory Key lecture: the indolent lymphomas
C. Thieblemont (Paris, FR)
- 11.35 Follicular lymphoma
S. Montoto (London, UK)
- 11.55 Marginal zone lymphoma
E. Zucca (Bellinzona, CH)
- 12.15 Bispecific antibodies in indolent lymphomas
TBD
- 12.35 Localized Hodgkin lymphoma: reduce toxic events while maintaining outstanding results
U. Ricardi (Torino)
- 12.55 Advanced Hodgkin lymphoma: how to choose first-line therapy to achieve the 90% cure goal
A. Pinto (Napoli)
- 13.15 Round table - Does target therapy mean 'no harm'?
Chairmen: A. Pulsoni (Roma), L. Rigacci (Roma)
Discussants: TBD, S. Montoto (London, UK), A. Pinto (Napoli),
U. Ricardi (Torino), C. Thieblemont (Paris, FR), E. Zucca (Bellinzona, CH)

13.45 Lunch

SESSION V: DIFFICULT-TO-DIAGNOSE AND DIFFICULT-TO-TREAT LYMPHOMAS

Chairmen: M. Spina (Aviano-PN), U. Vitolo (Candiolo-TO)

- 14.30 Introductory key lecture: aggressive B-cell lymphomas
A. Rosenwald (Würzburg, Germany)
- 14.50 Gray-zone lymphomas
- Diagnosis - E. Sabbatini (Bologna)
- Treatment – P.L. Zinzani (Bologna)
- 15.30 The double-hit and the double expressor
- Diagnosis - A. Di Napoli (Roma)
- Treatment: M. Balzarotti (Milano)
- 16.10 Mantle cell lymphoma with poor prognosis (blastoid morphology, p53 mutation, high proliferation index): How can we exploit target therapies (BTKi, BCL2i, T-cell-engagers)?
C. Visco (Verona)
- 16.30 Peripheral T-cell lymphomas
- Diagnosis – S. Pileri (Milano-Bologna)
- Treatment – F. D’Amore (Aarhus, DK)
- 17.10 Round table: what are the biologic risk factors and how do we stratify our therapy?
Chairmen: S. Pileri (Milano-Bologna), P.L. Zinzani (Bologna)
Discussants: F. D’Amore (Aarhus, DK), A. Di Napoli (Roma), S. Pileri (Milano-Bologna),
A. Rosenwald (Würzburg, Germany), E. Sabbatini (Bologna), C. Visco (Verona)
- 17.40 Conclusions
S. Hohnhaus (Roma), M. Martelli (Roma), L. Rigacci (Roma)